Examination of four newly synthesized 2-chloroethylnitrosoureas in comparison with BCNU, CCNU, MeCCNU, chlorozotocin and hydroxyethyl-CNU in preterminal rat leukemia L 5222.
The newly synthesized nitrosoureas 1-(2-chloroethyl)-1-nitroso-3-(methylenecarboxamido)-urea (Acetamido-CNU), 1-(2-chloroethyl)-1-nitroso-3-(4-morpholino)-urea (Morpholino-CNU), 1-(2-chloroethyl)-1-nitroso-3-(1-piperidino)-urea (Piperidino-CNU), and 2-[3-(2-chloroethyl)-3-nitrosoureido]-ethylmethanesulfonate (Ethylmethanesulfonato-CNU) were compared in their chemotherapeutic activity against preterminal rat leukemia L 5222 with BCNU, CCNU, MeCCNU, Chlorozotocin, and Hydroxyethyl-CNU. With respect to the dose range effecting a median survival time of more than 90 days, MeCCNU was superior to the other substances. Chlorozotocin, on the other hand, was the only substance which achieved no cures in this experimental arrangement. From the four newly introduced substances the water-soluble substances Acetamido-CNU and Morpholino-CNU were approximately comparable to CCNU with regard to the dose range effecting a median survival time of greater than 90 days. Piperidino-CNU and Ethylmethanesulfonato-CNU also effected cures; however, only Piperidino-CNU in one dosage effected a median survival time of greater than 90 days.
D000818:Animals; D002330:Carmustine / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D005260:Female; D007942:Leukemia, Experimental / Q000188:drug therapy*; D008130:Lomustine / Q000627:therapeutic use; D008297:Male; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D051381:Rats; D012673:Semustine / Q000627:therapeutic use; D013311:Streptozocin / Q000031:analogs & derivatives / Q000627:therapeutic use
D009607:Nitrosourea Compounds; D012673:Semustine; D013311:Streptozocin; D008130:Lomustine; D002330:Carmustine